Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Baron-Hay S, Aapro M, Bernareggi A, Schwartzberg L.

Support Care Cancer. 2019 Apr;27(4):1309-1317. doi: 10.1007/s00520-019-4640-8. Epub 2019 Jan 26.


Oral liquid formulation of levothyroxine is stable in breakfast beverages and may improve thyroid patient compliance.

Bernareggi A, Grata E, Pinorini MT, Conti A.

Pharmaceutics. 2013 Dec 13;5(4):621-33. doi: 10.3390/pharmaceutics5040621.


Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.

Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A, CassarĂ  PG, D'Arasmo G, Ferretti E, De Munari S, Oliva A, Pezzoni G, Allievi C, Strepponi I, Ruggeri B, Ator MA, Williams M, Mallamo JP.

J Med Chem. 2008 Feb 28;51(4):1068-72. doi: 10.1021/jm7010589. Epub 2008 Feb 5.


CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G.

Blood. 2008 Mar 1;111(5):2765-75. Epub 2007 Dec 5.


A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.

Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH.

Clin Cancer Res. 2005 Nov 1;11(21):7834-40.


Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.

Singer JW, Shaffer S, Baker B, Bernareggi A, Stromatt S, Nienstedt D, Besman M.

Anticancer Drugs. 2005 Mar;16(3):243-54. Review.


Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).

Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, Bernareggi A.

Anticancer Drugs. 2004 Jan;15(1):15-22.


Supplemental Content

Loading ...
Support Center